State of the Science in Cervical Cancer: Where We Are Today and Where We Need to Go

被引：43

作者：

Dizon, Don S. ^{[1
,2
]}

Mackay, Helen J. ^{[3
,4
]}

Thomas, Gillian M. ^{[5
,6
]}

Werner, Theresa L. ^{[7
]}

Kohn, Elise C. ^{[8
]}

Hess, Dina ^{[9
]}

Rose, Peter G. ^{[10
]}

Covens, Allan L. ^{[11
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Gillette Ctr Gynecol Oncol, Boston, MA 02114 USA

[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA

[3] Princess Margaret Hosp, Div Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada

[4] Univ Toronto, Dept Med, Toronto, ON, Canada

[5] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Toronto, ON, Canada

[6] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Obstet & Gynecol, Toronto, ON, Canada

[7] Univ Utah, Sch Med, Dept Med, Div Oncol, Salt Lake City, UT USA

[8] NCI, Clin Invest Branch, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, Bethesda, MD 20892 USA

[9] NCI, Gynecol Oncol Steering Comm, EMMES Corp, Rockville, MD USA

[10] Cleveland Clin Fdn, Dept Obstet & Gynecol, Div Gynecol Oncol, Cleveland, OH 44195 USA

[11] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Gynecol Oncol, Dept Obstet & Gynecol, Toronto, ON, Canada

来源：

CANCER | 2014年 / 120卷 / 15期

关键词：

cervical cancer; clinical trials; human papillomavirus; immunotherapy; anti-angiogenesis; screening; prevention; PELVIC RADIATION-THERAPY; PHASE-III TRIAL; PLUS CISPLATIN; RIBONUCLEOTIDE REDUCTASE; CONCURRENT CHEMOTHERAPY; ADJUVANT GEMCITABINE; IMMUNE-RESPONSES; ONCOLOGY-GROUP; IVA CARCINOMA; STAGE IIB;

D O I：

10.1002/cncr.28722

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Invasive cervical cancer remains an important global cause of death, despite the declining prevalence within the United States. Definitive therapies, including surgical resection of early-stage disease and chemoradiation for locally advanced disease, can be curative. For women who experience local or distant recurrences, the prognosis remains poor and better treatments are required. On July 18, 2013, The Gynecologic Oncology Group sponsored a State of the Science in Cervical Cancer Symposium with experts, researchers, clinicians, and interested stakeholders. This article summarize the progress that has been made, questions that require further investigation, and contemporary genomic findings and innovative treatments that may help inform the next generation of clinical trials for patients with cervical cancer. (C) 2014 American Cancer Society.

引用

页码：2282 / 2288

页数：7

共 37 条

[1] Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis [J].

Alberts, David S. ;

Brady, Mark ;

Cikaric, Slobodan ;

Chen, Hongwei ;

Dinshaw, Ketayun ;

Eifel, Patricia J. ;

Garipagaoglu, Melahat ;

Jakobsen, Anders ;

Kantardzic, Nermina ;

Keys, Henry ;

Lal, Punita ;

Lanciano, Rachelle ;

Leborgne, Felix ;

Lorvidhaya, Vicharn ;

Onishi, Hiroshi ;

Parmar, Mahesh K. B. ;

Pearcey, Robert G. ;

Pras, Elizabeth ;

Roberts, Kenneth ;

Rose, Peter G. ;

Stewart, Lesley A. ;

Tierney, Jayne F. ;

Thomas, Gillian ;

Trimble, Ted ;

Vale, Claire ;

Whitney, Charles W. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01)

[2]

[Anonymous], 2017, N Engl J Med, V377, P702, DOI 10.1056/NEJMx170002

[3]

[Anonymous], CA CANC J CLIN, DOI DOI 10.3322/CAAC.20107

[4]

Basu P, 2012, 2012 AM SOC CLIN ONC

[5] Immunotherapy for gynaecological malignancies [J].

Coukos, G ;

Conejo-Garcia, JR ;

Roden, RBS ;

Wu, TC .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (09) :1193-1210

[6] Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chernoradiotherapy plus adjuvant gemcitabine and cisplatin: Prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial [J].

Duenas-Gonzalez, A. ;

Orlando, M. ;

Zhou, Y. ;

Quinlivan, M. ;

Barraclough, H. .

GYNECOLOGIC ONCOLOGY, 2012, 126 (03) :334-340

[7] Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix [J].

Duenas-Gonzalez, Alfonso ;

Zarba, Juan J. ;

Patel, Firuza ;

Alcedo, Juan C. ;

Beslija, Semir ;

Casanova, Luis ;

Pattaranutaporn, Pittayapoom ;

Hameed, Shahid ;

Blair, Julie M. ;

Barraclough, Helen ;

Orlando, Mauro .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (13) :1678-1685

[8] ADENOCARCINOMA AS AN INDEPENDENT RISK FACTOR FOR DISEASE RECURRENCE IN PATIENTS WITH STAGE IB CERVICAL-CARCINOMA [J].

EIFEL, PJ ;

BURKE, TW ;

MORRIS, M ;

SMITH, TL .

GYNECOLOGIC ONCOLOGY, 1995, 59 (01) :38-44

[9] HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies [J].

English, Diana P. ;

Roque, Dana M. ;

Santin, Alessandro D. .

MOLECULAR DIAGNOSIS & THERAPY, 2013, 17 (02) :85-99

[10] Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study [J].

Farley, John ;

Sill, Michael W. ;

Birrer, Michael ;

Walker, Joan ;

Schilder, Russell J. ;

Thigpen, J. Tate ;

Coleman, Robert L. ;

Miller, Brigitte E. ;

Rose, Peter G. ;

Lankes, Heather A. .

GYNECOLOGIC ONCOLOGY, 2011, 121 (02) :303-308

← 1 2 3 4 →